# Priority Paywalled Papers for VAI ↔ MAGNIFI-CD Crosswalk

Papers identified that likely contain valuable paired scoring data but require institutional access or purchase.

## HIGH PRIORITY (n>30, both indices, validation studies)

### 1. Fibrosis and MAGNIFI-CD Activity Index Study (2022)
- **Title:** Fibrosis and MAGNIFI-CD Activity Index at Magnetic Resonance Imaging to Predict Treatment Outcome in Perianal Fistulizing Crohn's Disease Patients
- **Authors:** van Rijn KL et al.
- **Journal:** J Crohns Colitis. 2022 Jun 24;16(5):708-716
- **DOI:** 10.1093/ecco-jcc/jjab182
- **PubMed:** 34644395
- **PMC:** PMC9228904 (OPEN ACCESS - already extracted!)
- **Why valuable:** n=50 patients, paired MAGNIFI-CD and Fibrosis scores, AUC=0.95 for MAGNIFI-CD predicting outcome
- **Key data:** MAGNIFI-CD closed=0 (IQR 0-5), open=16 (IQR 10-20); Fibrosis 100%=all closed

### 2. External Validation of MAGNIFI-CD (2024/2025)
- **Title:** External validation of the MAGNIFI-CD index in patients with complex perianal fistulising Crohn's disease
- **Authors:** Beek KJ et al.
- **Journal:** Eur Radiol. 2025 Mar;35(3):1428-1439
- **DOI:** 10.1007/s00330-024-11029-3
- **PMC:** PMC11836172 (OPEN ACCESS - already extracted!)
- **Why valuable:** n=65 patients, ICC=0.87, effect size 1.11, correlations with rVAS (r=0.86-0.93)
- **Key data:** Baseline MAGNIFI-CD responders=20 vs non-responders=20; Post-treatment responders=9

### 3. Modified Van Assche Index Evaluation (2019)
- **Title:** Evaluation of the modified Van Assche index for assessing response to anti-TNF therapy with MRI in perianal fistulizing Crohn's disease
- **Authors:** Samaan MA et al.
- **Journal:** Clin Imaging. 2020 Mar;59(1):114-120
- **DOI:** 10.1016/j.clinimag.2019.11.009
- **PubMed:** 31821976
- **Why valuable:** Compares VAI, mVAI performance; n unclear but focuses on response assessment
- **Key finding:** 38% of clinical responders had equal/increased mVAI (worse than MAGNIFI-CD's 20%)

### 4. P325 ECCO 2022 Abstract - VAI vs mVAI vs MAGNIFI-CD
- **Title:** Performance of new MRI scores: the modified Van Assche Index and the MAGNIFI-CD in the evaluation of the response to anti-TNFα in anoperineal fistulas in Crohn's disease
- **Authors:** Mtir M et al.
- **Conference:** ECCO Congress 2022
- **Journal:** J Crohns Colitis. 2022;16(Suppl 1):i346
- **DOI:** 10.1093/ecco-jcc/jjab232.459
- **Why valuable:** n=38 (26 responders, 12 non-responders), AUROC comparison VAI=0.925, mVAI=0.908, MAGNIFI-CD=0.869
- **Key finding:** All three indices comparable for response assessment

## MEDIUM PRIORITY (Smaller n, useful supporting data)

### 5. Infliximab Effectiveness by MRI (2019)
- **Title:** Evaluating the effectiveness of infliximab on perianal fistulizing Crohn's disease by magnetic resonance imaging
- **Authors:** Zhu MF et al.
- **Journal:** World J Gastroenterol. 2019;25(8):948-956
- **DOI:** 10.3748/wjg.v25.i8.948
- **PMC:** PMC6375345 (OPEN ACCESS)
- **PubMed:** 30792866
- **Why valuable:** Van Assche score decreased from 14.5±4.26 to 7.36±7.53 post-treatment
- **Key data:** Chinese cohort, 6 infliximab treatments

### 6. Ustekinumab Radiological Healing (2023)
- **Title:** Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn's Disease
- **Authors:** Li Y et al.
- **Journal:** J Clin Med. 2023;12(3):817
- **PMC:** PMC9917613 (OPEN ACCESS - already extracted!)
- **Why valuable:** n=67 with MRI, Van Assche decreased from 9.0 to 5.5 (p<0.001)
- **Key data:** 44.8% radiological healing, 31.4% partial response

### 7. Long-term Monitoring with MRI (2010)
- **Title:** Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging
- **Authors:** Ng SC et al.
- **Journal:** Inflammatory Bowel Diseases. 2011;17(6):1339-1346
- **PubMed:** 21056696
- **Why valuable:** Long-term follow-up with serial MRI scores
- **Key finding:** T2 hyperintensity most responsive component

### 8. Higher Anti-TNF Levels and Radiologic Outcomes (2021)
- **Title:** Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas
- **Authors:** Yarur AJ et al.
- **Journal:** Clinical Gastroenterology and Hepatology
- **DOI:** 10.1016/j.cgh.2021.08.012
- **Why valuable:** Correlates drug levels with MRI improvement using VAI

## LOWER PRIORITY (Reviews, smaller datasets)

### 9. MRI Role Review (2018)
- **Title:** Role of magnetic resonance imaging in the management of perianal Crohn's disease
- **Authors:** Defined et al.
- **Journal:** Insights into Imaging
- **PMC:** PMC5825308 (OPEN ACCESS)
- **Why valuable:** Comprehensive review of scoring systems

### 10. Scoring Indices Systematic Review (2024)
- **Title:** Scoring Indices for Perianal Fistulising Crohn's Disease: A Systematic Review
- **Authors:** Various
- **Journal:** J Crohns Colitis. 2024;18(6):836
- **DOI:** 10.1093/ecco-jcc/jjad201
- **Why valuable:** Comprehensive comparison of all indices

---

## Summary of Available Data Points

| Paper | n | VAI Data | MAGNIFI-CD Data | Paired? |
|-------|---|----------|-----------------|---------|
| van Rijn 2022 | 50 | No | Yes (medians) | MAGNIFI-CD + Fibrosis |
| Beek 2024 | 65 | No | Yes (medians, ICC) | MAGNIFI-CD + rVAS |
| Mtir 2022 | 38 | AUROC | AUROC | All 3 comparable |
| Zhu 2019 | ? | Mean±SD | No | VAI only |
| Li 2023 | 67 | Median(IQR) | No | VAI only |
| Protocolized (extracted) | 60 | Median(IQR) | Median(IQR) | YES - PAIRED |

## Key Findings for Crosswalk

1. **VAI and MAGNIFI-CD are highly correlated** (r≥0.60 for change scores)
2. **MAGNIFI-CD has better reliability** (ICC 0.74-0.87 vs 0.67-0.68 for VAI)
3. **MAGNIFI-CD has better responsiveness** (effect size 1.02-1.11 vs 0.68 for VAI)
4. **Fibrosis is key:** 100% fibrotic tracts = clinical closure
5. **AUROC comparison:** VAI 0.925, mVAI 0.908, MAGNIFI-CD 0.869 (comparable)

## Papers to Contact Authors For Patient-Level Data

1. **van Rijn et al. 2022** - Has individual fibrosis + MAGNIFI-CD data (PISA-II trial)
2. **Beek et al. 2024** - 65 patients with detailed MAGNIFI-CD scoring
3. **Original MAGNIFI-CD 2019** (Hindryckx) - 160 patients, ADMIRE-CD trial cohort
4. **Samaan et al. mVAI** - Modified VAI development cohort
